Merck KGaA, Darmstadt, Germany, Named a Global Top Employer
- Top Employers Institute honors Merck KGaA, Darmstadt, Germany as Global Top Employer 2019
- Scored particularly well regarding talent development, performance management, and career and succession planning
- Additional Top Employer certifications for the regions Asia-Pacific, Europe, the Middle East, and North and Latin America
Darmstadt, Germany, February 6, 2019 – Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced it has been named one of only 14 global employers of choice by the Top Employers Institute. The annual Global Top Employer certification recognizes companies that have shown excellence in people practices and structures worldwide. Merck KGaA, Darmstadt, Germany has been awarded this certification for the third consecutive time. The Top Employers Institute particularly recognized the company’s achievements in talent development, performance management, and career and succession planning. Besides the certification as Global Top Employer 2019, the group also received the certifications Top Employer Europe 2019 and Top Employer Germany 2019.
“Our leadership in science and technology is the direct result of having a highly qualified team of motivated people committed to coming up with new ideas to make the world better,” said Belén Garijo, CEO Healthcare and member of the Executive Board responsible for HR at Merck KGaA, Darmstadt, Germany. “Such external recognition will enhance even further our ability to bring on board the talent that allows us to constantly challenge the status quo.”
The annual international research undertaken by the Top Employers Institute recognizes leading employers around the world through a stringent evaluation process. Including more than 1,500 companies across 118 countries, this evaluation is based on a detailed assessment of HR processes and structures and focuses on criteria such as talent strategy, career and succession planning, executive development, onboarding, personnel planning, training and development, corporate culture, compensation and benefits, and performance management.
As well as being named a Global Top Employer 2019, Merck KGaA, Darmstadt, Germany has also received regional certifications in Asia-Pacific, Europe, Latin America, the Middle East, and North America. In addition to these certifications, in 2018 the company was ranked among the top five employers in the biotechnology and pharmaceutical industry by Science magazine.
Further information on the Top Employer Institute and its certifications at: https://www.top-employers.com/de/
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 51,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2017, Merck KGaA, Darmstadt, Germany, generated sales of € 15.3 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Two new strategic drug discovery collaborations aim at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities.